WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/040947    International Application No.:    PCT/CA1999/000101
Publication Date: 19.08.1999 International Filing Date: 11.02.1999
Chapter 2 Demand Filed:    10.09.1999    
A61K 51/08 (2006.01)
Applicants: RESOLUTION PHARMACEUTICALS INC. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario LV4 1V7 (CA) (For All Designated States Except US).
FAUCONNIER, Theresa [CA/CA]; (CA) (For US Only).
POLLAK, Alfred [CA/SI]; (SI) (For US Only).
THORNBACK, John [GB/CA]; (CA) (For US Only).
ESHIMA, Dennis [US/CA]; (CA) (For US Only)
Inventors: FAUCONNIER, Theresa; (CA).
POLLAK, Alfred; (SI).
ESHIMA, Dennis; (CA)
Agent: DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA)
Priority Data:
60/074,420 11.02.1998 US
Abstract: front page image
(EN)The present invention relates to compounds that are effective for targeting sites of angiogenesis for diagnostic and therapeutic purposes. The compounds are of the Formula (I): A-(B)n-C, wherein A is a chelator moiety capable of complexing a radionuclide metal or a moiety capable of binding to a halogen; B is a spacer group; C is an angiogenesis targeting molecule; and n is selected from the integers 0 and 1. The invention also relates to a method of imaging sites of angiogenesis and treating patients through the administration of the compounds of the present invention.
(FR)La présente invention concerne des composés efficaces pour cibler des sites d'angiogénèse à des fins diagnostiques et thérapeutiques. Les composés ont la formule suivante (I): A-(B)n-C, dans laquelle A représente une fraction de chélateur capable de complexer un métal de radionucléide ou une fraction capable de se fixer à un halogène; B représente un groupe espaceur; C représente une molécule ciblant l'angiogénèse et n est choisi entre les nombres entiers 0 et 1. L'invention concerne également un procédé d'imagerie de sites d'angiogénèse et de traitement de patients par l'administration des composés de la présente invention.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)